The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.
An article from
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.
Published June 23, 2026
Pfizer Inc. signage is seen on July 22, 2020 in New York City.
Jeenah Moon via Getty Images
Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients - Pfizer (NYSE:
Closely watched Pfizer lung cancer drug falls short in clinical trial
Pfizer Stock Trades Flat Following Mixed Phase 3 Lung Cancer Trial Data - Pfizer (NYSE:PFE)
Pfizer scores 1st expansion in 7 years for breast cancer blockbuster Ibrance
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
Pfizer's sigvotatug vedotin missed its Phase 3 OS goal in NSCLC but showed encouraging results in second-line patients.
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet…
Pfizer said an experimental drug it hoped could replace a widely used chemotherapy in one of the most common forms of lung cancer…
Pfizer has pursued deals of all sizes to build new revenue streams, but the outlook underscores that those investments are still…
Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results…
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
